| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
SGLT2
SGLT-2 (sodium-glucose cotransporter-2). Enavogliflozin is a potent and selective inhibitor of SGLT-2, the primary transporter responsible for glucose reabsorption in the kidney. By selectively blocking SGLT-2, the compound reduces renal glucose reabsorption, leading to increased urinary glucose excretion and subsequent lowering of plasma glucose levels. This mechanism is insulin-independent, making it an attractive therapeutic approach for type 2 diabetes management. |
|---|---|
| ln Vitro |
The antidiabetic medication enavogliflozin (DWP-16001) is an oral, potent, highly selective, and best-in-class sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].
Enavogliflozin demonstrates potent inhibitory activity against SGLT-2, as a first-in-class and best-in-class SGLT-2 inhibitor. While specific IC50 values are not detailed in the available literature, the compound's selectivity for SGLT-2 over SGLT-1 is a key feature of its pharmacological profile. By selectively targeting SGLT-2, it effectively reduces glucose reabsorption in the kidney without significantly affecting intestinal glucose absorption mediated by SGLT-1. |
| ln Vivo |
In vivo, Enavogliflozin has demonstrated antidiabetic efficacy in preclinical models of type 2 diabetes. As an orally active compound, it is administered via the oral route, and its glucose-lowering effects are mediated through increased urinary glucose excretion. The compound is currently under clinical development for the treatment of type 2 diabetes mellitus, with clinical trials ongoing to evaluate its efficacy and safety.
|
| Enzyme Assay |
In vitro enzyme activity assays for Enavogliflozin typically involve measuring its ability to inhibit SGLT-2-mediated glucose uptake. These assays are performed using cells that express recombinant human SGLT-2, and the compound's inhibitory potency is determined by measuring the reduction in radiolabeled glucose or methyl-α-D-glucopyranoside uptake in the presence of increasing concentrations of the compound. Selectivity over SGLT-1 is confirmed using similar assays with SGLT-1-expressing cells.
|
| Cell Assay |
Cellular assays for Enavogliflozin involve the use of cell lines that express SGLT-2, such as human embryonic kidney (HEK) cells stably transfected with the human SGLT-2 gene. These cells are incubated with the compound in the presence of radiolabeled glucose or a fluorescent glucose analog, and the inhibition of glucose uptake is measured to determine the compound's potency and selectivity. This approach confirms the compound's ability to functionally inhibit SGLT-2-mediated glucose transport in a cellular context.
|
| Animal Protocol |
In vivo efficacy of Enavogliflozin has been evaluated in preclinical animal models of type 2 diabetes, such as db/db mice or streptozotocin-induced diabetic rats. The compound is administered orally, and blood glucose levels are monitored over time to assess its glucose-lowering effects. Urinary glucose excretion is also measured to confirm the mechanism of action. The compound has demonstrated antidiabetic efficacy in these models and is currently under clinical investigation.
|
| ADME/Pharmacokinetics |
Enavogliflozin has a molecular formula of C24H27ClO6 and a molecular weight of 446.92. It is orally active, indicating good oral bioavailability. The compound is supplied with a purity of ≥99%. As a small-molecule SGLT-2 inhibitor, its pharmacokinetic properties support once-daily oral dosing for the management of type 2 diabetes. The compound is currently in clinical development, and further pharmacokinetic data will be established from ongoing clinical trials.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for Enavogliflozin is detailed in the available literature. As a SGLT-2 inhibitor, its safety profile would be expected to be similar to other members of this drug class, which are generally well-tolerated with common adverse effects including urinary tract infections, genital mycotic infections, and volume depletion-related events. Standard preclinical and clinical toxicology studies have been conducted as part of its clinical development program.
|
| References | |
| Additional Infomation |
Enalapril is being studied in the clinical trial NCT06399835 (Effects of Enalapril vs. Pioglitazone on Glucose and Atherosclerosis). It is a novel sodium-glucose cotransporter 2 inhibitor; currently undergoing clinical development for the treatment of type 2 diabetes. See also: Canagliflozin (related drugs); Tolpagliflozin (related drugs).
Enavogliflozin (also known as DWP-16001) is a first-in-class, orally active, and selective SGLT-2 inhibitor being developed as a best-in-class antidiabetic agent. It has the molecular formula C24H27ClO6 and a molecular weight of 446.92. The compound is currently under clinical investigation for the treatment of type 2 diabetes mellitus, with clinical trial NCT06399835 evaluating Enavogliflozin versus Pioglitazone on glucose and atherosclerosis. It is a research compound not yet approved for clinical use. |
| Molecular Formula |
C24H27CLO6
|
|---|---|
| Molecular Weight |
446.92
|
| Exact Mass |
446.149
|
| CAS # |
1415472-28-4
|
| PubChem CID |
71076840
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
666.1±55.0 °C at 760 mmHg
|
| Flash Point |
356.7±31.5 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.666
|
| LogP |
4.9
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
609
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1CC1C2=CC=C(C=C2)CC3=CC(=C4CCOC4=C3Cl)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O
|
| InChi Key |
KORCWPOBTZTAFI-YVTYUBGGSA-N
|
| InChi Code |
InChI=1S/C24H27ClO6/c25-19-15(9-12-1-3-13(4-2-12)14-5-6-14)10-17(16-7-8-30-23(16)19)24-22(29)21(28)20(27)18(11-26)31-24/h1-4,10,14,18,20-22,24,26-29H,5-9,11H2/t18-,20-,21+,22-,24+/m1/s1
|
| Chemical Name |
(2S,3R,4R,5S,6R)-2-[7-chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-1-benzofuran-4-yl]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (223.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2375 mL | 11.1877 mL | 22.3754 mL | |
| 5 mM | 0.4475 mL | 2.2375 mL | 4.4751 mL | |
| 10 mM | 0.2238 mL | 1.1188 mL | 2.2375 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT06399835
Conditions:Type 2 DiabetesLink: https://clinicaltrials.gov/ct2/show/NCT07213310
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT06027307
Conditions:Tricuspid Regurgitation|Heart Failure With Preserved Ejection Fraction
Title:ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement
Status:Recruiting
updateDate:2025-12-15
Ctid:NCT05672836
Link: https://clinicaltrials.gov/ct2/show/NCT05672836
Conditions:Aortic Valve Stenosis|Heart FailureLink: https://clinicaltrials.gov/ct2/show/NCT07240844
Conditions:Amyloid CardiomyopathyLink: https://clinicaltrials.gov/ct2/show/NCT05926414
Conditions:Diabetes Mellitus, Type 2Link: https://clinicaltrials.gov/ct2/show/NCT06427083
Conditions:Type 2 Diabetes MellitusLink: https://clinicaltrials.gov/ct2/show/NCT06782139
Conditions:Obesity and Type 2 DiabetesLink: https://clinicaltrials.gov/ct2/show/NCT06647888
Conditions:Diabetes Mellitus, Type 2Link: https://clinicaltrials.gov/ct2/show/NCT06580717
Conditions:Nonobstructive Hypertrophic CardiomyopathyLink: https://clinicaltrials.gov/ct2/show/NCT06644404
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT06642623
Conditions:Diabetes Mellitus, Type 2|Cardiovascular Diseases|Kidney DiseasesLink: https://clinicaltrials.gov/ct2/show/NCT06606093
Conditions:Type 2 Diabetic NephropathyLink: https://clinicaltrials.gov/ct2/show/NCT06528262
Conditions:Atrial FibrillationLink: https://clinicaltrials.gov/ct2/show/NCT05466643
Conditions:Type 2 Diabetes MellitusLink: https://clinicaltrials.gov/ct2/show/NCT05747664
Conditions:Diabetes Mellitus, Type 2Link: https://clinicaltrials.gov/ct2/show/NCT05505994
Conditions:Diabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism Disorders|Metabolic Disease|Endocrine System DiseasesLink: https://clinicaltrials.gov/ct2/show/NCT06141980
Conditions:T2DM (Type 2 Diabetes Mellitus)Link: https://clinicaltrials.gov/ct2/show/NCT05797922
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT05737771
Conditions:FDC|Diabetes Mellitus, Type 2Link: https://clinicaltrials.gov/ct2/show/NCT04632862
Conditions:T2DM (Type 2 Diabetes Mellitus)Link: https://clinicaltrials.gov/ct2/show/NCT05376969
Conditions:T2DM (Type 2 Diabetes Mellitus)Link: https://clinicaltrials.gov/ct2/show/NCT05500898
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT05192395
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT05321732
Conditions:Healthy VolunteersLink: https://clinicaltrials.gov/ct2/show/NCT05207176
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT04343547
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT04064073
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT04221399
Conditions:Type2 DiabetesLink: https://clinicaltrials.gov/ct2/show/NCT03364985
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT04014023
Conditions:T2DM (Type 2 Diabetes Mellitus)Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
